OSUR
Hot AirOraSure Technologies, Inc. · Healthcare · United States · $285M cap · $2.2M/day traded
$3.56 +6.9% · close 11 Nov · scored 12 Nov
Score up 1.8 since 11 Nov.
Hot Air: Strong momentum and nothing else: weak business, rich price.
As of 12 Nov 2026, the MoatMap Score for OraSure Technologies, Inc. (OSUR) is 42/100, ranked against 25,000+ stocks in 38 markets (Quality 34, Value 39, Momentum 62, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT ORASURE TECHNOLOGIES, INC.
Read
OraSure Technologies, Inc. develops, manufactures, and markets a broad range of diagnostic products and collection devices, primarily focused on oral fluid technology for infectious diseases like HIV and COVID-19, and substance abuse. The company holds a competitive edge through its proprietary oral fluid collection platforms and established market presence in point-of-care diagnostics, catering to both clinical and consumer markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 387.5M | 405.5M | 185.8M | 115.0M | -33.3% | 112.4M | 121.3M | 130.6M | 6.5% |
| EPS | -0.25 | 0.73 | -0.26 | -0.94 | — | -0.69 | -0.80 | -0.63 | — |
| Shares | 72.7M | 73.5M | 74.6M | 70.4M | -3.2% | 69.0M | — | — | — |
| Debt | 12.5M | 13.5M | 14.6M | 13.2M | 1.7% | 12.1M | — | — | — |
| Equity | 364.4M | 430.7M | 410.3M | 340.8M | -2.2% | — | — | — | — |
| Op CF | -47.2M | 141.6M | 27.4M | -49.0M | -80.7% | -42.9M | — | — | — |
| Inv CF | 21.1M | 66.2M | -39.0M | -6.8M | — | — | — | — | — |
| Fin CF | -3.8M | -3.0M | -4.2M | -16.9M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 64% of stocks we rank over the past year (volatility 51% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OSUR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| OSUR | OraSure Technologies, Inc.(you) | $285M | 42 |
| ANGO | AngioDynamics, Inc. | $520M | 35 |
| SMTI | Sanara MedTech Inc. | $301M | 61 |
| KRMD | KORU Medical Systems, Inc. | $146M | 35 |
| STAA | STAAR Surgical Company | $1.1B | 33 |
| DXR | Daxor Corporation | $54M | 36 |
| POCI | Precision Optics Corporation, Inc. | $52M | 35 |
| AZTA | Azenta, Inc. | $1.6B | 48 |
| LMAT | LeMaitre Vascular, Inc. | $1.9B | 49 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 31 |
Peer medians: ROE -31.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.